Cantourage Group Past Earnings Performance
Past criteria checks 4/6
Cantourage Group has been growing earnings at an average annual rate of 402%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 63.1% per year. Cantourage Group's return on equity is 0.5%, and it has net margins of 11.3%.
Key information
402.0%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 63.1% |
| Return on equity | 0.5% |
| Net Margin | 11.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Cantourage Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2 | 0 | 1 | 0 |
| 31 Mar 24 | 2 | 0 | 1 | 0 |
| 31 Dec 23 | 2 | 0 | 1 | 0 |
| 30 Sep 23 | 1 | 0 | 1 | 0 |
| 30 Jun 23 | 1 | 0 | 0 | 0 |
| 31 Dec 22 | 1 | 0 | 0 | 0 |
| 31 Dec 21 | 5 | -1 | 1 | 0 |
Quality Earnings: HIGH has high quality earnings.
Growing Profit Margin: HIGH's current net profit margins (11.3%) are higher than last year (3.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HIGH has become profitable over the past 5 years.
Accelerating Growth: Insufficient data to compare HIGH's past year earnings growth to its 5-year average.
Earnings vs Industry: HIGH earnings growth over the past year (402%) exceeded the Pharmaceuticals industry 25.4%.
Return on Equity
High ROE: HIGH's Return on Equity (0.5%) is considered low.